Research Alliance Corp III (NASDAQ: RACC) is set to acquire 100% of OHB Pediatrics Ltd., valuing the target at a base equity of $160,000,000. This strategic move, which includes RACC's domestication to Delaware, aims to enhance its market position and has spurred significant investor interest, with shares rallying today. The transaction is expected to finalize in the second half of 2026.

Key Highlights

  • Research Alliance Corp III (NASDAQ: RACC) is acquiring 100% of OHB Pediatrics Ltd. in a business combination valued at a base equity of $160,000,000.
  • The deal requires RACC to domesticate from the Cayman Islands to Delaware and convert its shares to common stock with a par value of $0.0001 per share.
  • RACC shares have seen substantial gains, building on a 27.9% year-to-date increase and 25.0% over the past month.
  • The acquisition is slated for completion in the second half of 2026, pending RACC shareholder approval and regulatory clearances.

Research Alliance Corp III (NASDAQ: RACC) announced a definitive agreement to acquire 100% of OHB Pediatrics Ltd. a move poised to reshape the special purpose acquisition company. The transaction establishes OHB Pediatrics’ base equity value at $160,000,000, with the consideration to be paid in newly issued RACC common stock. This strategic acquisition, approved unanimously by both companies' boards, signals a clear direction for RACC as it transitions toward becoming an operating entity focused on the pediatric sector.

The anticipated completion in the second half of 2026 hinges on shareholder and regulatory endorsements, representing a significant inflection point for RACC’s market trajectory.

Strategic Pediatric Acquisition

The business combination agreement, entered into on July 26, 2026, stipulates that Research Alliance Corp III will acquire all outstanding shares of OHB Pediatrics Ltd. a company incorporated under England and Wales laws, identified by company number 15958711. Shareholders of OHB Pediatrics will transfer 100% of their equity in exchange for shares of RACC common stock. This comprehensive acquisition strategy aims to integrate OHB Pediatrics entirely into RACC, making it a wholly-owned subsidiary upon closing.

The merger is designed to position RACC firmly within the pediatric market, broadening its operational scope and potential for future growth within a specialized healthcare niche.

Transaction Mechanics and Valuation

Before the acquisition's closing, Research Alliance Corp III plans to undergo a domestication process, transferring its registration from the Cayman Islands to Delaware. This involves converting its existing Class A ordinary shares into common stock, each with a par value of $0.0001 per share. The consideration for the share acquisition will be determined by dividing the Adjusted Equity Value, which includes the base equity value of $160,000,000, by $10.00.

This structure allows RACC shareholders to redeem their Class A shares for cash from a trust account, providing liquidity options. The shift to a Delaware corporation is a common practice for SPACs, simplifying the legal framework for the combined entity and aligning it with typical U.S. corporate governance standards.

Market Reaction and Outlook

Investors have responded positively to the announcement, pushing Research Alliance Corp III shares higher. This daily gain builds on an impressive performance throughout the year, with RACC shares up 27.9% year-to-date and climbing 25.0% over the past month, placing its current market capitalization at $100 million. The company's 52-week trading range spans $10.21 to $13.47, indicating that current levels are near its recent highs. This sustained upward momentum suggests that the market views the OHB Pediatrics acquisition as a strategic accelerator, potentially enhancing RACC's valuation beyond its current market cap by integrating a business with a substantial base equity value.

Road to Completion

The finalization of the business combination is subject to several customary closing conditions. Key among these are the receipt of requisite approvals from RACC’s shareholders and regulatory clearance, specifically the expiration or termination of the waiting period. RACC's common stock must be approved for listing on The Nasdaq Capital Market.

Investors should closely monitor the progress toward these milestones, as any delays could impact the expected second half of 2026 closing timeframe for the pediatric healthcare transaction.

Analysis based on the Form 8-K filed 27 July 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.